POLYGAM 3G POWDER FOR INJECTION
triamcinolone
What it does
Triamcinolone is a corticosteroid used to reduce inflammation and treat various conditions.
Commonly used for: inflammation, allergic reactions, skin disorders, asthma …
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Botswana Medicines Regulatory Authority · fetched 2026-04-15 20:41:48 · updated 2026-05-12 08:02:26
Drug Interactions
41Pharmacodynamic Warnings
Triamcinolone appears in TABLE 17: Drugs that reduce serum potassium
Severe (1)
Mifamurtide - decreases efficacy
Corticosteroidsarepredictedtodecreasetheefficacyof mifamurtide.Avoid.rTheoretical
Moderate (20)
Corticosteroids - increases exposure
Dronedarone is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - increases concentration
Miconazole is predicted to increase the concentration of corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - increases exposure
Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - decreases exposure
Cenobamate is predicted to decrease the exposure to corticosteroids (fluticasone). Adjust dose.
Corticosteroids - decreases efficacy
Mifepristone is predicted to decrease the efficacy of corticosteroids. Use with caution and adjust dose.
Unknown (20)
Aspirin - decreases concentration
Corticosteroids are predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with corticosteroids.
Choline Salicylate - decreases concentration
Corticosteroids are predicted to decrease the concentration of cholinesalicylate. Ciclesonide → see corticosteroids Ciclosporin → see TABLE 2 p. 1517 (nephrotoxicity), TABLE 16 p. 1521 (increased seru
Corticosteroids - increases exposure
Cobicistat is predicted to increase the exposure to corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids).
Corticosteroids - increases risk of gastrointestinal perforation
Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with corticosteroids.
Corticosteroids - increases exposure
Idelalisib is predicted to increase the exposure to corticosteroids (betamethasone, budesonide, ciclesonide, deflazacort, dexamethasone, fludrocortisone, fluticasone, hydrocortisone, methylprednisolon
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class
About this medicine
Triamcinolone is a corticosteroid used to reduce inflammation and treat various conditions.
What it treats
- inflammation
- allergic reactions
- skin disorders
- asthma
- arthritis
How it works
It works by suppressing the immune system to reduce inflammation and allergic responses.
Who it's for
Triamcinolone is for people with conditions that involve inflammation or an overactive immune response.
Drug class
Corticosteroids
Cautions
- • Be cautious if you are taking other medications that lower potassium levels.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: triamcinolone
BNF-referencedTriamcinolone is a synthetic corticosteroid that exhibits potent anti-inflammatory properties. It is used in various clinical conditions to reduce inflammation and suppress immune responses. As a member of the glucocorticoid family, triamcinolone acts by modulating gene expression and inhibiting the synthesis of inflammatory mediators. Its therapeutic applications include treatment of diseases like asthma, allergies, autoimmune disorders, and dermatological conditions among others.
Indications
- Asthma
- Allergic rhinitis
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Dermatitis
- Psoriasis
- Inflammatory bowel disease
Dosage
Children: Refer to BNF for Children for specific dosing recommendations based on condition and formulation.
Adults: Refer to BNF for specific dosing recommendations based on condition and formulation.
Mechanism of action
Triamcinolone inhibits phospholipase A2 on cell membranes, preventing the breakdown of lysosomal membranes of leukocytes. This action reduces the formation of arachidonic acid, leading to decreased expression of cyclooxygenase and lipoxygenase, which inhibits the synthesis of prostaglandins and leukotrienes. Additionally, triamcinolone inhibits nuclear factor kappa-B, reducing pro-inflammatory signals such as interleukin-6 and interleukin-8. It interacts with specific intracellular receptor proteins to alter the expression of corticosteroid-responsive genes, leading to the synthesis of proteins like lipocortin that further inhibit inflammatory pathways.
Pharmacodynamics
Triamcinolone exhibits significant anti-inflammatory effects through multiple mechanisms, including suppression of immune cell migration and modulation of inflammatory mediator production. Its effects can lead to reduced edema, erythema, and pain associated with inflammatory processes. The drug’s action is mediated by its ability to influence gene expression in target tissues, resulting in a broad range of effects on the immune response and inflammation.
Pharmacokinetics
Triamcinolone is well absorbed following parenteral administration, with peak plasma concentrations typically observed within a few hours. It has a relatively long half-life, which allows for sustained therapeutic effects. The drug is metabolized primarily in the liver and excreted via the kidneys. Its pharmacokinetic profile may vary depending on the route of administration and the specific formulation used.
Interactions
- mitotane+triamcinolone: Moderate (decreases exposure)
- rifampicin+triamcinolone: Moderate (decreases exposure)
- cobicistat+triamcinolone: Unknown (increases exposure)
- idelalisib+triamcinolone: Unknown (increases exposure)
- clarithromycin+triamcinolone: Unknown (increases exposure)
Pregnancy
Corticosteroids, including triamcinolone, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. They may cause fetal harm, particularly when used in high doses or for prolonged periods in the second and third trimesters.
Breast-feeding
Triamcinolone is excreted in human milk, and caution should be exercised when administering to nursing mothers. The benefits of breastfeeding should be weighed against the potential risk of adverse effects on the infant.
Storage
Store at room temperature, away from light and moisture. Do not freeze.
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: triamcinolone
PubChem CID 31307Molecular formula: C21H27FO6
Mechanism of action
Corticosteroids like triamcinolone inhibit phospholipase A2 on cell membranes, preventing the breakdown of lysosomal membranes of leukocytes, which in turn prevent the formation of arachidonic acid, which decrease expression of cyclooxygenase and lipoxygenase, inhibiting synthesis of prostaglandins and leukotrienes. Anti-inflammatory activity occurs via reversal of vascular dilation and reducing permeability, which prevents macrophage and leukocyte migration. Triamcinolone also inhibits nuclear factor kappa-B, which decreases the production of pro-inflammatory signals such as interleukin-6, interleukin-8, and monocyte chemoattractant protein-1. Glucocorticoids are capable of suppressing the inflammatory process through numerous pathways. They interact with specific intracellular receptor proteins in target tissues to alter the expression of corticosteroid-responsive genes. Glucocorticoid-specific receptors in the cell cytoplasm bind with steroid ligands to form hormone-receptor complexes that eventually translocate to the cell nucleus. There these complexes bind to specific DNA sequences and alter their expression. The complexes may induce the transcription of mRNA leading to synthesis of new proteins. Such proteins include lipocortin, a protein known to inhibit PLA2a and thereby block the synthesis of prostaglandins, leukotrienes, and PAF. Glucocorticoids also inhibit the production of other mediators including AA metabolites such as COX, cytokines, the interleukins, adhesion molecules, and enzymes such as collagenase. /Glucocorticoids/ Corticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of messenger RNA (mRNA) and subsequent protein synthesis of various inhibitory enzymes responsible for the anti-inflammatory effects of topical corticosteroids. These anti-inflammatory effects include inhibition of early processes such as edema, fibrin deposition, capillary dilatation, movement of phagocttes into the area, and phagocytic activities. Later processes, such as capillary production, collagen deposition, and keloid formation also are inhibited by corticosteroids. The overall actions of topical corticosteroids are catabolic. /Corticosteroids (topical)/ The potent anti-inflammatory action may be due to an inhibition of the secretion of growth factors, endothelial activating and other cytokines from lymphocytes, eosinophils, macrophages, fibroblasts, and mast cells. The results are decreased influx of inflammatory cells into the bronchial walls, due in part to inhibition of expression of adhesion molecules on the endothelium and in the tissue. Decreased activation and survival of eosinophils in the lung tissue and a reduction in numbers of mast cells are further effects. Corticosteroids may inhibit release of mediators from basophils and enzymes from macrophages. There is decreased permeability through vasoconstriction and direct inhibition of endothelial cell contradiction. Beta-adrenergic-receptor numbers may be increased, which results in an enhanced response to beta-adrenergic bronchodilators and reduced down-regulation of beta-receptors after prolonged beta-agonist exposure. Inhaled corticosteroids also inhibit mucus secretion in airways, possibly by a direct action on submucosal gland cells and an indirect inhibitory effect caused by the reduction in inflammatory mediators that stimulate mucus secretion. The amount and viscosity of sputum are reduced. /Corticosteroids (inhalation-local/
Pharmacodynamics
Triamcinolone is a corticosteroid with anti-inflammatory properties. These properties are used to treat inflammation in conditions that affect various organs and tissues. Triamcinolone should not be administered as an epidural injection.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- CORTIN NASAL SPRAY · Dolopharma
- KEMZID CREAM · Omaera Pharmaceuticals
- POSITON CREAM · Phillips Therapeutics
- S-CORT · Salama Pharmaceuticals
- TESS BUCCAL PASTE · Harleys
- TRIAM-DENK 40 INJECTION · Laborex Kenya
- D-CORT_40 40MG INJECTION
- ECONAZINE 10MG, 1MG/G CREAM
- HOLLEYCORT 40MG/ML INJECTION
- KENALOG 1MG PASTE
- PANDERM COMBINATION PRODUCT OINTMENT
- TESS 0.1%W/W BUCCAL PASTE
- Demtris Cream · Laboratorios Vitoria
- Econazine Cream · Y. S. P. Industries
- Safi · Seoul Pharma
- Safi cream · Seoul Pharma Company Limited
- TESS · Troika Pharmaceuticals
- TRIAMACORT · Lincoln Pharmaceuticals
- DERMX CREAM (Each gram contains Econazole Nitrate/Triamcinolone Acetonide/Gentamicin Sulfate 1%w/w/0.1%w/w/0.1%w/w) · S Kant Healthcare
- DERMX CREAM (Each gram contains Econazole Nitrate/Triamcinolone Acetonide/Gentamicin Sulfate 1%w/w/0.1%w/w/0.1%w/w · S Kant Healthcare
- POSITON CREAM · Faes Farma
- TRIAM - DENK 40MG INJECTION (Each vial contains triamcinolone acetrude 40mg · Fisco Pharma